AllergoOncology is a combination of allergy and oncology. The relationship between allergy and tumor has been discussed and studied decades ago. In the 1960s a negative correlation between allergy and tumor morbidity was first discovered. Since then there has been an endless stream of related researches on basic translational and clinical medicine in this field. In 2014 a Task Force on AllergoOncology was established at the European Association of Allergy and Clinical Immunology EAACI led by Professor Erika Jensen-Jarolim aiming to establish a routine platform for allergy oncology achievements. Focusing on the intersection of allergy and oncology the working group is dedicated to research on immune surveillance immune regulation and IgE-mediated tumor immune responses and has issued 5 position papers on AllergoOncology. It has promoted the transformation of the core theory of allergy into clinical practical cancer treatment and is expected to further improve the therapeutic efficacy efficacy of tumors. This article interprets the position papers of AllergoOncology from the negative correlation between allergy and tumor effectors cells and molecules and microbiota in allergy and cancer and translational strategies in AllergoOncology based on novel insights into the field of AllergoOncology.